AI Portfolio Summary
In 2025 Q4, MPM BioImpact LLC maintained a portfolio of 55 distinct positions. The most significant new addition to the portfolio was Agios Pharmaceutical, which now represents 4.06% of the total fund value. They heavily accumulated shares in Liquidia Corp, increasing their position by 600.4%. Conversely, MPM BioImpact LLC completely exited their position in Assembly Biosciences.
Total Positions
55
Quarter
2025 Q4
Top Holding
CGEM (9.1%)
Top 10 Concentration
49.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 55
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CGEM
Cullinan Therap...
|
Healthcare | 9.06% | 7.42% |
#1
1
Prev: #2
|
6.6 | no change | no change |
P
S
|
7,648,268 | $79,159,574 | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 6.45% | 7.54% |
#2
1
Prev: #1
|
4.6 | -3,635 | -3.6% |
P
S
|
96,780 | $56,358,865 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LQDA
Liquidia Corp
|
Healthcare | 5.53% | 0.74% |
#3
29
Prev: #32
|
6.2 | 1,200,869 | 600.4% |
P
S
|
1,400,869 | $48,315,972 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
Trevi Therapeut...
|
Healthcare | 4.71% | 5.10% |
#4
Prev: #4
|
2.9 | -119,868 | -3.5% |
P
S
|
3,287,087 | $41,154,329 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
Edgewise Therap...
|
Healthcare | 4.70% | 4.57% |
#5
Prev: #5
|
2.9 | -65,485 | -3.8% |
P
S
|
1,655,256 | $41,075,178 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
Revolution Medi...
|
Healthcare | 4.61% | 2.41% |
#6
13
Prev: #19
|
4.8 | 189,950 | 60.2% |
P
S
|
505,672 | $40,276,775 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
Agios Pharmaceu...
|
Healthcare | 4.06% | — |
#7
Prev: #—
|
5.1 | 1,303,373 | no change |
NEW
|
1,303,373 | $35,477,813 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QURE
Uniqure NV
|
Healthcare | 3.78% | — |
#8
Prev: #—
|
5.0 | 1,381,628 | no change |
NEW
|
1,381,628 | $33,062,358 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTCT
PTC Therapeutic...
|
Healthcare | 3.74% | 4.41% |
#9
3
Prev: #6
|
2.0 | -8,464 | -1.9% |
P
S
|
430,013 | $32,663,787 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
Syndax Pharmace...
|
Healthcare | 3.22% | 3.46% |
#10
2
Prev: #8
|
1.8 | -37,972 | -2.8% |
P
S
|
1,337,702 | $28,105,119 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 3.15% | 3.00% |
#11
2
Prev: #13
|
1.8 | -40,973 | -2.8% |
P
S
|
1,405,388 | $27,489,389 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
Tarsus Pharmace...
|
Healthcare | 3.08% | 3.32% |
#12
2
Prev: #10
|
1.7 | -12,627 | -3.7% |
P
S
|
328,869 | $26,927,794 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
STOK
Stoke Therapeut...
|
Healthcare | 2.80% | 3.04% |
#13
1
Prev: #12
|
1.6 | -19,409 | -2.5% |
P
S
|
770,289 | $24,448,973 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
Alumis Inc
|
Healthcare | 2.68% | — |
#14
Prev: #—
|
4.6 | 2,401,992 | no change |
NEW
|
2,401,992 | $23,443,442 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
Urogen Pharma L...
|
Healthcare | 2.52% | 0.44% |
#15
22
Prev: #37
|
4.0 | 806,378 | 597.3% |
P
S
|
941,378 | $22,047,073 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
Xenon Pharmaceu...
|
Healthcare | 2.49% | 3.31% |
#16
5
Prev: #11
|
1.5 | -17,778 | -3.5% |
P
S
|
485,620 | $21,765,488 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PVLA
Palvella Therap...
|
Healthcare | 2.46% | 0.69% |
#17
16
Prev: #33
|
4.0 | 138,322 | 205.2% |
P
S
|
205,745 | $21,535,329 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTRA
Natera Inc
|
Healthcare | 2.45% | 2.61% |
#18
1
Prev: #17
|
1.5 | -5,373 | -5.4% |
P
S
|
93,551 | $21,431,599 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRVS
Corvus Pharmace...
|
Healthcare | 2.42% | — |
#19
Prev: #—
|
4.5 | 2,743,671 | no change |
NEW
|
2,743,671 | $21,126,267 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DBVT
DBV Technologie...
|
Healthcare | 2.19% | 1.73% |
#20
7
Prev: #27
|
1.4 | -57,679 | -5.5% |
P
S
|
996,825 | $19,109,135 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RLAY
Relay Therapeut...
|
Healthcare | 2.16% | 1.95% |
#21
3
Prev: #24
|
1.4 | -50,229 | -2.2% |
P
S
|
2,232,451 | $18,886,535 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 2.11% | — |
#22
Prev: #—
|
4.3 | 1,173,376 | no change |
NEW
|
1,173,376 | $18,398,536 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 2.06% | — |
#23
Prev: #—
|
4.3 | 230,147 | no change |
NEW
|
230,147 | $17,960,672 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
Protagonist The...
|
Healthcare | 1.99% | — |
#24
Prev: #—
|
4.3 | 199,471 | no change |
NEW
|
199,471 | $17,421,797 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
enGene Holdings...
|
Healthcare | 1.90% | 0.59% |
#25
11
Prev: #36
|
3.8 | 1,310,599 | 247.1% |
P
S
|
1,840,898 | $16,623,309 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTX
Context Therap...
|
Healthcare | 1.80% | 2.33% |
#26
6
Prev: #20
|
0.7 | -4,026,491 | -27.4% |
P
S
|
10,679,391 | $15,698,705 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
Arcutis Biother...
|
Healthcare | 1.77% | — |
#27
Prev: #—
|
4.2 | 531,200 | no change |
NEW
|
531,200 | $15,426,048 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
Ventyx Bioscien...
|
Healthcare | 1.69% | — |
#28
Prev: #—
|
4.2 | 1,639,061 | no change |
NEW
|
1,639,061 | $14,800,721 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
Oric Pharmaceut...
|
Healthcare | 1.68% | 3.40% |
#29
20
Prev: #9
|
1.2 | 69,339 | 4.0% |
P
S
|
1,798,717 | $14,713,505 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BLTE
Belite Bio Inc
|
Healthcare | 1.61% | — |
#30
Prev: #—
|
4.1 | 87,760 | no change |
NEW
|
87,760 | $14,038,090 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT Therapeuti...
|
Healthcare | 1.54% | — |
#31
Prev: #—
|
4.1 | 397,906 | no change |
NEW
|
397,906 | $13,477,076 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLYM
Climb Bio Inc
|
Healthcare | 1.22% | — |
#32
Prev: #—
|
4.0 | 2,671,480 | no change |
NEW
|
2,671,480 | $10,685,920 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
Abivax SA
|
Healthcare | 0.87% | — |
#33
Prev: #—
|
3.8 | 56,316 | no change |
NEW
|
56,316 | $7,594,494 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCKT
Rocket Pharmace...
|
Healthcare | 0.64% | 2.08% |
#34
11
Prev: #23
|
0.3 | -2,317,305 | -59.4% |
P
S
|
1,586,076 | $5,567,127 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
Maze Therapeuti...
|
Healthcare | 0.38% | — |
#35
Prev: #—
|
3.7 | 81,145 | no change |
NEW
|
81,145 | $3,361,837 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EVMN
Evommune Inc
|
Healthcare | 0.22% | — |
#36
Prev: #—
|
3.6 | 113,022 | no change |
NEW
|
113,022 | $1,934,937 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRPT
Sarepta Therape...
|
Healthcare | 0.17% | 2.21% |
#37
16
Prev: #21
|
0.1 | -630,000 | -90.0% |
P
S
|
70,000 | $1,506,400 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HOWL
Werewolf Therap...
|
Healthcare | 0.10% | 0.78% |
#38
7
Prev: #31
|
0.0 | -1,015,253 | -42.1% |
P
S
|
1,393,557 | $883,515 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASMB
Assembly Biosci...
|
Healthcare | 0.00% | 0.17% |
Sold All 😨
(Was: #40) |
0.0 | -39,665 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RPTX
Repare Therapeu...
|
Healthcare | 0.00% | 0.24% |
Sold All 😨
(Was: #39) |
0.0 | -819,924 | -100.0% |
CLOSED
|
— | $— | 2020 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPP
Rapport Therape...
|
Healthcare | 0.00% | 0.35% |
Sold All 😨
(Was: #38) |
0.0 | -71,807 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNAC
Cartesian Thera...
|
Healthcare | 0.00% | 0.64% |
Sold All 😨
(Was: #35) |
0.0 | -380,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DSGN
Design Therapeu...
|
Healthcare | 0.00% | 0.68% |
Sold All 😨
(Was: #34) |
0.0 | -555,187 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKBA
Akebia Therapeu...
|
Healthcare | 0.00% | 1.29% |
Sold All 😨
(Was: #30) |
0.0 | -2,889,125 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLDB
Solid Bioscienc...
|
Healthcare | 0.00% | 1.65% |
Sold All 😨
(Was: #29) |
0.0 | -1,634,569 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
Soleno Therapeu...
|
Healthcare | 0.00% | 1.66% |
Sold All 😨
(Was: #28) |
0.0 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
Wave Life Scien...
|
Healthcare | 0.00% | 1.80% |
Sold All 😨
(Was: #26) |
0.0 | -1,505,262 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.00% | 1.95% |
Sold All 😨
(Was: #25) |
0.0 | -395,700 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPRY
ARS Pharmaceuti...
|
Healthcare | 0.00% | 2.14% |
Sold All 😨
(Was: #22) |
0.0 | -1,303,399 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JANX
Janux Therapeut...
|
Healthcare | 0.00% | 2.46% |
Sold All 😨
(Was: #18) |
0.0 | -614,282 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 55 holdings